Showing posts with label Liver. Show all posts
Showing posts with label Liver. Show all posts

Sunday, May 1, 2016

Singapore - $7.5 million to be pumped into liver cancer research

SINGAPORE - A Singapore-based team researching the most common type of liver cancer has been awarded a $7.5 million grant to continue its studies, it was announced on Wednesday.

Professor Pierce Chow, a senior consultant surgeon with National Cancer Centre Singapore (NCCS) is leading a multi-disciplinary team comprising clinicians and researchers from several institutions to carry out in-depth studies on the genomics and immunology of liver cancer.

A pilot study into the most common type of liver cancer, Hepatocellular Carcinoma or HCC, has found significant heterogeneity within tumours.This means different parts of the same cancer may have different genetic mutations or produce different immune response.

It explains why current approaches to drug development in HCC have not been fruitful, according to Professor Pierce Chow.

The team has been awarded a $7.5 million grant under the TCR Flagship Programme grant by Singapore's National Medical Research Council (NMRC).

Its research will involve five centres from Singapore and the region and start in the third quarter of this year. The study will be conducted using tumour samples from 100 patients.

The effort could enable doctors to predict the outcome of therapies and help them select appropriate treatments, said Prof Chow.

"Through this translational clinical research, we hope to find an answer to the shortage of efficacious therapies and the challenges of bringing precision medicine to patients with HCC," said Prof Chow.

The team aims to create customised therapies for individual liver cancer patients within the next five years.

In Singapore, 500 new liver cancer patients are diagnosed each year.

It is the fourth most common cancer among men in Singapore. Between 2010 and 2014, 2,254 men were diagnosed with it. It is less common in women and is not within the top 10 cancers in women.

Between 2010 and 2014, 2,516 people died from this form of cancer.



Friday, November 23, 2012

International - Paper Test Could Make Drug Treatment Safer


Researchers have developed a finger-prick blood sample device to detect serious liver damage.

Researchers looking to make tuberculosis (TB) and HIV treatment safer have developed a paper-based test for drug-induced liver damage.

Standard treatments for TB such as rifampicin and pyrazinamide can cause liver damage, particularly in people co-infected with hepatitis B or C, which are common in Asia.

Similarly, patients can experience liver damage if they are treated for HIV with commonly used nevirapine-based drugs.

Yet clinicians in developing countries rarely have easy access to tests for drug-induced liver injury, said Nira Pollock, assistant professor of medicine at Harvard Medical School in the United States.

US doctors routinely check for high levels of chemical markers in blood that show if patients are developing serious liver damage, and then adjust their medication accordingly.

Now, researchers have developed and tested a stamp-sized paper device with channels and wells that mix, split, and filter a finger-prick blood sample to detect these chemical markers.

The trial used existing blood samples to compare the device to standard tests. It showed an overall accuracy of more than 90 percent compared with the gold standard of 100 percent.

It takes just 15 minutes to get the color changes that indicate normal, moderate, or high levels of liver markers. The test also includes a control that confirms the test was accurate.

The estimated cost of each test is just ten US cents, compared with upfront costs of thousands of dollars for existing point-of-care mini laboratory devices.

Jason Rolland, senior director of research from Diagnostics For All, which developed the technology, said the test is cheap, easy to use, and portable, with no need for electricity or instrumentation.

“It is designed to be used in a rural clinic to support our mission in the developing world,” he added.

Usually liver function testing for patients in rural areas requires samples to be sent to large hospitals, and they can get lost en route, said Rolland. He added that drug-induced liver damage rates are between ten and 25 percent in the developing world, compared to around two percent of patients being treated for TB in the developed world.

Pollock coordinated the trial and is liaising with the National Hospital for Tropical Diseases in Vietnam to conduct field trials of the device in patients suffering from HIV.

If the test works as well in patients, the researchers are hoping to have a commercial product in 2014.
Currently, Diagnostics for All is able to manufacture 500 to 1,000 tests per day.

Commenting on the research, Alison Grant, assistant professor of medicine at the London School of Hygiene and Tropical Medicine, said the technology “could be very useful for patients at high risk or thought to have liver damage.”

But she cautioned that not all patients benefit from routine liver function testing, and WHO guidelines recommend it only for patients at highest risk.

And the cost could be higher than stated.

“Experience of other point-of-care tests suggests that in addition to initial training, staff need refresher training periodically to be sure they are using the test correctly, and this support needs to be taken into account when estimating the true cost of the test,” Grant added.

Rachel Mundy



Sunday, November 11, 2012

Singapore - Mum claims spat with doctor lead to death of girl, 3


SINGAPORE - She was only three years old, and she was undergoing her second liver transplant.

Unfortunately, she developed complications after her transplant and died.

Wednesday was the coroner's inquiry into the death of Nadia Abdullah, who was born with a liver condition.

The coroner's court heard that Nadia had a history of biliary atresia - a congenital lack of bile ducts to drain bile from the liver.

She also had a medical history of beta-thalassaemia trait and iron-deficiency anaemia.

Nadia, who was born on Feb 7, 2006, underwent an operation about a month later to allow the drainage of bile from her liver, but it was not successful.

Her liver functions then began to fail. About two years later on April 10, 2008, her mother, Ms Norhayati Amir, donated part of her liver to her.

The liver transplant was carried out at the National University Hospital (NUH).

But various complications occurred - anaemia was noted about 18 months after the transplant, among others.

Soon, she needed a second transplant. She was put on the waiting list for a cadaver liver - liver donated by a donor who is brain-dead.

Within months, a suitable and matching liver was found on the evening of Jan 13, 2010. The donor was a 30-year-old healthy woman, who suffered a stroke of the brain.

Nadia was admitted into NUH again the next day, for a scheduled second liver transplant.

Did spat with doctor lead to toddler's death?

Professor K Prabhakaran, the head of department of Paediatric Surgery of NUH, performed the operation.

Dr Dale Lincoln Loh Ser Kheng, a senior consultant in the Department of Paediatric Surgery at NUH, assisted him together with other surgeons.

The operation went well, but Nadia's cardiovascular status became unstable.

She later became unresponsive and remained in the paediatric intensive care unit (ICU) of NUH until her death on Jan 29, 2010 - about 15 days after the second transplant.

But Ms Norhayati, 28, who is a nurse, was concerned over the cause of death of her daughter. She raised several issues.

She was concerned over whether Dr Loh had performed the second transplant properly because she had a spat with him in the morning of the operation.

This was over the issue of consent - Dr Loh had obtained the consent for the second liver transplant from Nadia's grandmother instead of her, as Ms Norhayati wasn't in NUH at that time.

When Ms Norhayati was asked to go to NUH urgently the next morning to give her consent, a quarrel ensued.

Quarrel

The quarrel was between her and Dr Loh over the urgency of the issue and why she was not asked for her consent the evening before.

Dr Loh confirmed that "he did not do anything knowingly" which would cause Nadia's death.

Also noted was his role as one of the assisting surgeons and not as the main surgeon.

Ms Norhayati was concerned over whether NUH had done any proper checks to ensure that the donor's liver was a suitablematch to Nadia.

Dr Loh confirmed that the liver was an appropriate and suitable match - the donor had the same blood type and was below 40 years old, among others.

An independent expert, Associate Professor Loh Tsee Foong, the head and senior consultant from the Children's ICU of KK Women's and Children's Hospital, added that the complications Nadia had suffered were not unexpected in liver transplant.

Apart from the frequency of monitoring of ammonia level, the overall care and management given to Nadia was reasonable, he said.

Ms Norhayati said she would not have agreed to the second transplant if she had been informed that the donor was lupus positive.

But an independent expert, Dr Ravishankar K Diddapur, consultant surgeon from the Specialist Surgery, clarified that a donor who is lupus positive is not known to affect a recipient and screening for lupus antibody is not recommended as the risk is considered small.

NUH also clarified in a report that the screening for lupus positivity was not one of the routine blood investigations in donor screening.

Ms Norhayati asked how Nadia had caught the superbug MRSA.

As Nadia had multiple admissions into the hospital, Dr Ravishankar said it was difficult to ascertain when and how she had got the infection.

Ms Norhayati asked if the cardiopulmonary resuscitation (CPR) done on Nadia could have caused bleeding in her brain and if the bleeding could have been managed medically.

Prof Loh said in his report dated May 7 this year that it is possible that CPR may result in intracranial bleeding, but it would be an unintended side effect.

He also stated that the bleeding area in the brain was small and did not appear to cause a significant pressure on the brain and neurosurgical intervention is more likely to be harmful than of benefit to Nadia.

Police do not suspect foul play in Nadia's death.

Before State Coroner Imran Abdul Hamid presented his findings, he offered his condolences to Ms Norhayati.

He then addressed her concern over the spat.

He said: "Despite the spat, it has not affected the transplant itself. The transplantation of the liver was done without any technical issue and did not bear cause of death."

But he also noted that it would be beneficial if Dr Loh had spoken to Ms Norhayati directly instead of to Nadia's grandmother.

He also noted that "a single parent's responsibility can be tremendous".

When the liver fails

Nadia died from multi-organ failure as the liver graft had failed to thrive and complications arose. The unstoppable events had then led to Nadia's death, he said.

Liver failure happens when large parts of the organ become damaged beyond repair and it is no longer able to function.

It is life-threatening and demands urgent medical care.

Most often, liver failure occurs gradually over many years.

But a rare condition known as acute liver failure occurs in as little as 48 hours and can be hard to detect initially.

The most common causes of chronic liver failure include hepatitis (B and C), cirrhosis (irreversible scarring of the liver), hemochromatosis (an inherited disorder that causes the body to absorb and store too much iron) and long-term alcohol consumption.

In children, it is caused by biliary atresia, a condition which begins soon after birth, where the bile ducts fail to develop normally and are unable to drain bile from the liver.

Early symptoms of liver failure include nausea, loss of appetite, fatigue and diarrhoea. These can develop into jaundice, mental disorientation or confusion and even coma "should the condition worsen".

For liver failure resulting from long-term deterioration, the initial treatment is to save whatever part of the liver that is still functioning.

Waiting list

If this is not possible, then a liver transplant is required.

As of March, more than 500 patients with organ failure are still waiting for donor organs.

Of these, 448 are on the National Kidney Transplant waiting list while on dialysis, while 28 are in the queue for new livers, six for hearts and 22 for corneas.

Chai Hung Yin

The New Paper

Monday, October 15, 2012

Vietnam - HCMC first adult liver transplant ends in success


After 13 hours of surgery, Ho Chi Minh City’s first adult liver transplant on a 53-year-old woman ended successfully at Cho Ray Hospital on October 12, Dr Nguyen Tan Cuong, head of the hospital’s surgery department, said at a press conference this morning.


The operation was conducted by Cho Ray doctors and their South Korean counterparts in ASAN Medical Center, Cuong said, adding that it took the same duration as a similar case performed in South Korea.

The recipient of the liver is Mrs. Cung Thi Kim Dinh, who suffered from liver failure since 2010, and the donor is her 22-year-old son D.H.L, a student of information technology at the HCMC Foreign Language and Informatics University.

Two hours after the operation, which began at 8:25 am last Friday and ended on 10:30 pm the same day, the son recovered and later ate some soup and drank some milk.

Two days after the surgery, Dinh practiced walking and managed to walk to the next room to visit her son.

Tests of blood and liver functions on Dinh after the surgery showed that her health is in normal state. She needs more care for about 2 weeks.

Meanwhile, the son will continue to be followed in isolation room for 7-10 days and will be discharged in around a month.

After 6-8 weeks, the son will have a regenerated liver that will be 60-80 percent of his original liver, Dr. Son said.

As previously reported, a 15-member group from the South Korean center arrived in HCMC on October 11 to join their Vietnamese counterparts for the transplant surgery a day later.

TUOI TRE

Friday, June 1, 2012

Singapore – Japan – China - Scientists Sequence Genome Of Liver Cancer Caused By Hepatitis B, C


Two teams of Asian researchers have independently completed whole-genome sequencing studies of a type of liver cancer commonly caused by hepatitis virus infection.

Two teams of Asian researchers, one Japanese and the other from China and Singapore, have independently completed large-scale, whole-genome sequencing studies of a type of liver cancer commonly caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.

Both studies were published this week in Nature Genetics, providing important insights into how hepatitis viral infection causes hepatocellular carcinoma (HCC), the most common form of liver cancer worldwide, and may lead to improvements in diagnosis and treatment.

Individuals infected with HBV and HCV are known to have a significantly higher risk of developing HCC.

In countries like China and other parts of Asia where hepatitis B is endemic, HBV infection is the predominant cause of HCC.

In Japan, which has the highest HCC rates of any industrialized country in the world, HCV infection is thought to be responsible for the majority of cases.

It is thought that the HBV and HCV genomes are integrated into the genome of the human host in a manner that promotes the accumulation of genetic abnormalities, leading to cancer development.

The China-Singapore team studied tumor samples and adjacent normal tissues from 81 HBV-positive and 7 HBV-negative HCC patients while the Japanese team collected tumor and blood samples from 11 HBV-positive HCCs, 14 HCV-positive HCCs, and 2 HCCs that were not associated with hepatitis infection.

Both teams used whole-genome sequencing technologies to identify novel gene mutations that may be responsible for HCC development and pinpoint locations where the viral genome has been integrated into the host genome.

In particular, the China-Singapore team identified characteristics of HBV integrations that may help the virus to control specific genes in the host tumor, providing new insights into the mechanisms through which HBV integration promotes cancer.

“A deep understanding of the recurring HBV insertions in HCC will help the research community identify novel molecular targets in liver cancer, for which effective treatments are still limited,” said John Luk, a leader of the China-Singapore collaboration.


Copyright: Asian Scientist Magazine. Sources: BGINature Publishing Group.